DIRECT COSTS OF ERECTILE DYSFUNCTION IN A MANAGED CARE SETTING—EVIDENCE FROM A LARGE NATIONAL CLAIMS DATABASE
Sun P1, Selgel A2, Swindle R1, Ye W1, Pohl G1
1Lilly Research Laboratories, Indianapolis, IN, USA; 2Case Western Reserve University, School of Medicine, Cleveland, OH, USA

OBJECTIVES: To examine the direct costs of erectile dysfunction (ED) in a managed care setting. METHODS: A naturalistic and retrospective observational study was conducted with an ED cohort (285,436) of men age 18 or older and enrolled in 51 US health plans that covered 28 million lives from 1999 through 2001. Both annual costs of ED care per patient with ED and annual costs of ED care per user were measured for each category of ED-related care and treatments. RESULTS: On average, health plans spent $83.91, $95.41 and $119.26 on ED care for a patient with ED in 1999, 2000, and 2001 respectively. In 2001, an ED patient spent $44.22 on phosphodiesterase type 5 (PDE-5) inhibitor therapy, $14.56 on ED-related physicians’ evaluation and management, $0.13 on ED-related diagnosis procedures, $0.10 on ED-related testosterone therapy, $2.70 on intracavernosal injection, $1.49 on alprostadil pellet, $3.27 on penile prosthesis implantation, $0.72 on vacuum erection device, and $0.13 on ED-related vascular surgery (see Figure 1). Among seven common ED treatments, PDE-5 inhibitor had the lowest average annual costs per user of a treatment (see Figure 2). From 1999 through 2001, a health plan with 100,000 members might spend $320,865 (2000 dollars) on ED care, about one tenth of the costs forecasted by Tan ($3,204,792 in 1998 dollars). The largest per member per month cost of ED-related care and treatments was spent on ED-related vascular surgery ($2.70 in 2001), followed by testosterone therapy ($0.10 in 2001). CONCLUSIONS: In 2001, ED imposed a modest financial burden on a health plan ($122,699 for a plan with 100,000 members). Although the use of PDE-5 inhibitor therapy had the lowest annual treatment costs per user ($121.7 in 2001), it constituted 37.08% of the annual financial burden of ED (2001), followed by testosterone therapy (30.45% or $10,369).

HEALTH—Women’s

Pregnancy in Canada
Piwko C1, Ungar WJ1, Einarson TR1, Koren G1
1The Hospital for Sick Children, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada

OBJECTIVES: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy affecting an estimated 80% (50%–90%) of all pregnant women. Even with mild symptoms, NVP generates costs to society, patients and the health care system, and reduces quality of life. However, its costs are largely unknown. We estimated the total cost per woman-week associated with the onset of NVP in Canada, stratified by the self-reported severity (mild, moderate, severe) from the perspectives of society, Ministry of Health and Long Term Care (MoH), and patients. METHODS: Data were collected from 139 pregnant women, who called the Motherisk Program at the Hospital for Sick Children in Toronto. Motherisk is a teratology information and counseling service for all questions related to pregnancy. We collected the information about resource utilization for direct costs (drugs, physicians, hospitalizations) and indirect costs by telephone interviews. Costing was conducted with Ontario price lists and fee schedules. Indirect costs were calculated using the human capital approach and included absences from work and/or usual activities as well as reduced productivity at work. RESULTS: From the societal perspective, the costs per woman-week were $124, $334 and $610 for mild, moderate and severe NVP, respectively. From the MoH perspective, the costs were $4, $36, and $87, respectively. From the patient perspective, costs per woman-week were $110, $253 and $375, respectively. Costs from all perspectives increased with increasing NVP severity. Lost productivity constituted the largest cost component. CONCLUSIONS: NVP in Canada is associated with substantial costs to patients,